Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable leading edge research and accelerate biotherapeutic discovery and development.
The Company’s picodroplet incubation technology enables ultra-sensitive, rapid miniaturized assays of target protein secreted from tens of millions of individual cells.
Sphere Fluidics’ Cyto-Mine® System integrates isolation, selective screening, sorting, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Its Picodroplet Single Cell Analysis and Isolation System offers state-of-the-art microfluidics technology inside an easy-to-use, semi-automated system, designed with the flexibility to easily integrate into research processes.
Sphere Fluidics is located in Granta Park Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company is also internationalizing its business via a global network of distributors.